Management of hypertension in CAH should prioritize angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) due to their cardioprotective properties, beneficial effects on endothelial function, and ability to improve insulin sensitivity (321, 322). This evidence concerns the gene ACE and hypertensive disorder.